CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles

被引：0
作者：
Marc Terrones
Christophe Deben
Felicia Rodrigues-Fortes
Anne Schepers
Ken Op de Beeck
Guy Van Camp
Geert Vandeweyer
机构：
[1] University of Antwerp and Antwerp University Hospital,Center of Medical Genetics
[2] University of Antwerp and Antwerp University Hospital,Center for Oncological Research
来源：
Journal of Translational Medicine | / 22卷
关键词：
 + Non-small cell lung cancer; Tyrosine kinase inhibitors; CRISPR/Cas9; Drug resistance; 3D cell culture; 2D cell culture;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 201 条
[1]  
Drilon A(2021)ROS1-dependent cancers - biology, diagnostics and therapeutics Nat Rev Clin Oncol 18 35-55
[2]  
Jenkins C(2019)Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins Cancer Res 79 546-556
[3]  
Iyer S(2012)Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 4570-4579
[4]  
Schoenfeld A(2019)Crizotinib-induced immunogenic cell death in non-small cell lung cancer Nat Commun 10 1486-1971
[5]  
Keddy C(2020)Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med. 3 17-1483
[6]  
Davare MA(2020)Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies ESMO Open. 5 e000867-1236
[7]  
Neel DS(2014)Crizotinib in ROS1-rearranged non-small-cell lung cancer N Engl J Med 371 1963-17
[8]  
Allegakoen DV(2019)Entrectinib: first global approval Drugs 79 1477-615
[9]  
Olivas V(2018)Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Cancer Discov. 8 1227-368
[10]  
Mayekar MK(2020)Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? Precis Cancer Med 3 17-3347
12345678910